Macrophages and acylcarnitines: New players in aspirin-exacerbated respiratory disease?

J Allergy Clin Immunol. 2021 Feb;147(2):498-500. doi: 10.1016/j.jaci.2020.09.040. Epub 2020 Oct 27.

Authors

Tanya M Laidlaw¹, Barbara Balestrieri²

Affiliations

¹ Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: tlaidlaw@bwh.harvard.edu.
² Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

PMID: 33122084
DOI: 10.1016/j.jaci.2020.09.040

No abstract available

Keywords: AERD; acylcarnitines; eicosanoids; fatty acids; macrophages; type 2 inflammation.

Publication types

Editorial
Comment

MeSH terms

Aspirin / adverse effects
Asthma, Aspirin-Induced*
Carnitine / analogs & derivatives
Humans
Macrophages

Substances

acylcarnitine
Aspirin
Carnitine

Grants and funding

R56 HL113071/HL/NHLBI NIH HHS/United States